Preview Mode Links will not work in preview mode

This Week in Cardiology

May 13, 2022

Obstructive hypertrophic cardiomyopathy and mavacamten, SGLT2 inhibitors, the triple whammy, espresso, and clinician burnout are the topics John Mandrola, MD, covers in today’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I – Mavacamten

- FDA Clears Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy

- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

- FDA approves new drug to improve heart function in adults with rare heart condition

II – Dapagliflozin in HFpEF

- Positive Topline Results for Dapagliflozin in HFpEF: DELIVER

- Empagliflozin in Heart Failure with a Preserved Ejection Fraction

III – Triple Whammy for AKI

- Mixing BP Meds With NSAID May Be 'Triple Whammy' for Kidneys

IV – Espresso

- Espresso Coffee Associated With Increased Total Cholesterol

- Association between espresso coffee and serum total cholesterol: the Tromsø Study 2015–2016

- Is everything we eat associated with cancer? A systematic cookbook review

- Enough With the Coffee Research and Other Distractions

V – Clinician Burnout

- Administrative Hassle Hacks: Strategies to Curb Physician Stress

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact